Read more
Cancer is a multifaceted and genomically complex disease and data obtained through high throughput technologies has provided near complete resolution of the landscape of how genomic, genetic and epigenetic mutations in cancerous cells effectively influence homeostasis of signaling networks within these cells, between cancerous cells, tumor microenvironment and at the organ level. Increasingly sophisticated information has helped us in developing a better understanding of the underlying mechanisms of cancer, and it is now known that intra-tumor genetic heterogeneity, cellular plasticity, dysregulation of spatio-temporally controlled signaling cascades, and loss of apoptosis are contributory in cancer development, progression and the development of resistance against different therapeutics. It is becoming progressively more understandable that earlier detection of pre-existing or emerging resistance against different therapeutics may prove to be helpful in personalizing the use of targeted cancer therapy.
Despite the fact that there is a continuously increasing list of books, being guest edited by researchers, books on the subject are often composed of invited reviews without proper sequence and continuity and designed for a particular readership. This book progressively shifts and guides the readers from basic underlying mechanisms to translational approaches to treat cancer.
List of contents
- Microtubule targeting agents in cancer therapy: Elucidating the underlying molecular mechanisms.- Adenosine signaling pathways as potential therapeutic targets in cancer disease.- Anticancer activities of Hippophae rhamnoides: Journey from Benchtop to the Bedside.- Emerging role of ncRNAs in cancer biology: techniques for diagnostic monitoring and potential ncRNA-based therapies.- Clinical and translational research on the pathophysiology of several ocular tumors types.- Exosomes and cancer: from diagnosis to therapy.- Blood-based Cancer Detection: Towards Solving Diagnostic Puzzle.- Non-coding RNAs, Critical Therapy Targets against Cancer - Detection of Virus-caused Cancer in Publicly Available Next Generation Sequencing Data.- TRAIL mediated signaling in prostate cancer.- Index.
About the author
Ammad Ahmad Farooqiis currently a Senior Scientist at the Institute of Biomedical and Genetic Engineering (IBGE), in Islamabad, Pakistan. His area of research is tightly focused on cancer genetics and therapeutics.
Professor Muhammad Ismailhas a Ph.D. in Biotechnology and is currently the Director of the Institute of Biomedical and Genetic Engineering (IBGE), in Islamabad. His main focus of research is Cancer Genetics and Therapeutics, Nanomedicine and Pharmacogenomics.
Summary
Cancer is a multifaceted and genomically complex disease and data obtained through high throughput technologies has provided near complete resolution of the landscape of how genomic, genetic and epigenetic mutations in cancerous cells effectively influence homeostasis of signaling networks within these cells, between cancerous cells, tumor microenvironment and at the organ level. Increasingly sophisticated information has helped us in developing a better understanding of the underlying mechanisms of cancer, and it is now known that intra-tumor genetic heterogeneity, cellular plasticity, dysregulation of spatio-temporally controlled signaling cascades, and loss of apoptosis are contributory in cancer development, progression and the development of resistance against different therapeutics. It is becoming progressively more understandable that earlier detection of pre-existing or emerging resistance against different therapeutics may prove to be helpful in personalizing the use of targeted cancer therapy.
Despite the fact that there is a continuously increasing list of books, being guest edited by researchers, books on the subject are often composed of invited reviews without proper sequence and continuity and designed for a particular readership. This book progressively shifts and guides the readers from basic underlying mechanisms to translational approaches to treat cancer.
